Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 56 entries
View as:

A Clinical Trial in Healthy Volunteers and Volunteers with Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination with an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Phase: N/A Priority: Normal
NCT ID: NCT05432583 Org: User:
Start: 12/08/22 End: 10/31/26 Due: 10/31/27

A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm

Phase: N/A Priority: Normal
NCT ID: NCT06940804 Org: User:
Start: 07/31/25 End: 06/30/42 Due: 06/30/43

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Phase: N/A Priority: Normal
NCT ID: NCT04101357 Org: User:
Start: 06/19/20 End: 05/23/24 Due: 05/23/25

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

Phase: N/A Priority: Normal
NCT ID: NCT05472038 Org: User:
Start: 07/26/22 End: 03/26/24 Due: 03/26/25

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06750185 Org: User:
Start: 01/13/25 End: 06/30/28 Due: 06/30/29

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

Phase: N/A Priority: Normal
NCT ID: NCT04380701 Org: User:
Start: 04/23/20 End: 04/13/22 Due: 04/13/23

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

Phase: N/A Priority: Normal
NCT ID: NCT05630352 Org: User:
Start: 01/06/25 End: 07/13/26 Due: 07/13/27

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Phase: N/A Priority: Normal
NCT ID: NCT06178991 Org: User:
Start: 12/20/23 End: 11/26/24 Due: 11/26/25

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Phase: N/A Priority: Normal
NCT ID: NCT06069544 Org: User:
Start: 11/13/23 End: 03/31/26 Due: 03/31/27

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Phase: N/A Priority: Normal
NCT ID: NCT04534205 Org: User:
Start: 01/07/21 End: 04/30/29 Due: 04/30/30

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04523571 Org: User:
Start: 07/28/20 End: 08/10/21 Due: 08/10/22

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06841055 Org: User:
Start: 03/03/25 End: 10/31/28 Due: 10/31/29

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Phase: N/A Priority: Normal
NCT ID: NCT04368728 Org: User:
Start: 04/29/20 End: 02/10/23 Due: 02/10/24

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Phase: N/A Priority: Normal
NCT ID: NCT04955626 Org: User:
Start: 07/01/21 End: 05/25/23 Due: 05/25/24

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Phase: N/A Priority: Normal
NCT ID: NCT04754594 Org: User:
Start: 02/16/21 End: 07/15/22 Due: 07/15/23

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

Phase: N/A Priority: Normal
NCT ID: NCT05997290 Org: User:
Start: 08/10/23 End: 03/13/25 Due: 03/13/26

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06827236 Org: User:
Start: 04/23/25 End: 09/30/32 Due: 09/30/33

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05142189 Org: User:
Start: 06/17/22 End: 11/30/31 Due: 11/30/32

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06150183 Org: User:
Start: 11/30/23 End: 09/30/26 Due: 09/30/27

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

Phase: N/A Priority: Normal
NCT ID: NCT04649021 Org: User:
Start: 12/04/20 End: 01/09/22 Due: 01/09/23

Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06712355 Org: User:
Start: 02/03/25 End: 09/30/28 Due: 09/30/29

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

Phase: N/A Priority: Normal
NCT ID: NCT05541861 Org: User:
Start: 11/08/22 End: 11/22/24 Due: 11/22/25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06449222 Org: User:
Start: 08/26/24 End: 09/30/28 Due: 09/30/29

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04949490 Org: User:
Start: 07/26/21 End: 09/16/22 Due: 09/16/23

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04537949 Org: User:
Start: 09/09/20 End: 02/07/22 Due: 02/07/23